NO313635B1 - Sulfonamid-metalloprotease-inhibitorer, fremgangsmåter for fremstilling og anvendelse derav, og farmasöytiske preparater sominneholder dem - Google Patents

Sulfonamid-metalloprotease-inhibitorer, fremgangsmåter for fremstilling og anvendelse derav, og farmasöytiske preparater sominneholder dem Download PDF

Info

Publication number
NO313635B1
NO313635B1 NO19993587A NO993587A NO313635B1 NO 313635 B1 NO313635 B1 NO 313635B1 NO 19993587 A NO19993587 A NO 19993587A NO 993587 A NO993587 A NO 993587A NO 313635 B1 NO313635 B1 NO 313635B1
Authority
NO
Norway
Prior art keywords
alkyl
phenyl
hydrogen
compound according
sulfonyl
Prior art date
Application number
NO19993587A
Other languages
English (en)
Norwegian (no)
Other versions
NO993587L (no
NO993587D0 (no
Inventor
Chris Allen Broka
Jeffrey Allen Campbell
Arlindo Lucas Castelhano
Jian Jeffrey Chen
Robert Than Hendricks
Michael Joseph Melnick
Keith Adrian Murray Walker
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26713422&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO313635(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of NO993587D0 publication Critical patent/NO993587D0/no
Publication of NO993587L publication Critical patent/NO993587L/no
Publication of NO313635B1 publication Critical patent/NO313635B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04Diamides of sulfuric acids
    • C07C307/06Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Detergent Compositions (AREA)
NO19993587A 1997-01-23 1999-07-22 Sulfonamid-metalloprotease-inhibitorer, fremgangsmåter for fremstilling og anvendelse derav, og farmasöytiske preparater sominneholder dem NO313635B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3671497P 1997-01-23 1997-01-23
US6220997P 1997-10-16 1997-10-16
PCT/EP1998/000180 WO1998032748A1 (en) 1997-01-23 1998-01-14 Sulfamide-metalloprotease inhibitors

Publications (3)

Publication Number Publication Date
NO993587D0 NO993587D0 (no) 1999-07-22
NO993587L NO993587L (no) 1999-09-22
NO313635B1 true NO313635B1 (no) 2002-11-04

Family

ID=26713422

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19993587A NO313635B1 (no) 1997-01-23 1999-07-22 Sulfonamid-metalloprotease-inhibitorer, fremgangsmåter for fremstilling og anvendelse derav, og farmasöytiske preparater sominneholder dem

Country Status (35)

Country Link
EP (1) EP0958287B2 (is)
JP (1) JP3563411B2 (is)
KR (1) KR100377696B1 (is)
CN (1) CN1093125C (is)
AR (1) AR011425A1 (is)
AT (1) ATE223909T1 (is)
AU (1) AU730127B2 (is)
BG (1) BG103586A (is)
BR (1) BR9807508A (is)
CA (1) CA2278694C (is)
DE (2) DE69807845T2 (is)
DK (1) DK0958287T3 (is)
EA (1) EA002810B1 (is)
ES (2) ES2183331T3 (is)
FR (1) FR2758559A1 (is)
GB (1) GB2321641B (is)
HR (1) HRP980036A2 (is)
HU (1) HUP0000941A3 (is)
ID (1) ID22849A (is)
IL (1) IL130802A0 (is)
IS (1) IS5125A (is)
IT (1) IT1298163B1 (is)
MA (1) MA26467A1 (is)
NO (1) NO313635B1 (is)
NZ (1) NZ336625A (is)
OA (1) OA11078A (is)
PA (1) PA8445301A1 (is)
PE (1) PE57399A1 (is)
PL (1) PL334846A1 (is)
PT (1) PT958287E (is)
TN (1) TNSN98012A1 (is)
TR (1) TR199901765T2 (is)
UY (1) UY24854A1 (is)
WO (1) WO1998032748A1 (is)
YU (1) YU34599A (is)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
HN2000000052A (es) * 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
EP1187811B1 (en) 1999-06-04 2007-03-07 AstraZeneca AB Inhibitors of metalloproteinases
AU6764400A (en) * 1999-08-18 2001-03-13 Warner-Lambert Company Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
RU2283306C2 (ru) * 2000-02-21 2006-09-10 Астразенека Аб Пиперидин- и пиперазинзамещенные n-гидроксиформамиды в качестве ингибиторов металлопротеиназ
EP1274697A1 (en) * 2000-02-21 2003-01-15 AstraZeneca AB Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
US6495358B1 (en) * 2000-04-19 2002-12-17 Wichita State University Sulfamide and bis-sulfamide amino acid derivatives as inhibitors of proteolytic enzymes
AU4882101A (en) * 2000-04-28 2001-11-12 Shionogi & Co., Ltd. Mmp-12 inhibitors
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US6492171B2 (en) 2000-05-16 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of TERT expression
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
JP4219810B2 (ja) * 2001-10-26 2009-02-04 塩野義製薬株式会社 Mmp阻害作用を有するスルホンアミド誘導体
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
EP1511488B1 (en) 2002-06-12 2013-05-22 Symphony Evolution, Inc. Human adam-10 inhibitors
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
JP2007538054A (ja) * 2004-05-19 2007-12-27 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満および関係する病気の予防または治療のためのn−スルファモイル−n′−アリールピペラジンを含有する薬剤
BRPI0515488A (pt) * 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
DE102004060229A1 (de) 2004-12-15 2006-06-29 Sanofi-Aventis Deutschland Gmbh Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen
WO2007102392A1 (ja) 2006-03-03 2007-09-13 Shionogi & Co., Ltd. Mmp-13選択的阻害剤
EP2128134A1 (en) 2006-11-02 2009-12-02 Shionogi&Co., Ltd. Sulfonylurea derivative capable of selectively inhibiting mmp-13
WO2008147764A1 (en) * 2007-05-23 2008-12-04 Array Biopharma, Inc. Mmp inhibitors and methods of use thereof
WO2009050120A1 (de) 2007-10-12 2009-04-23 Basf Se Verfahren zur herstelung von sulfonsäurediamiden
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
EP2456757B1 (en) * 2009-07-22 2019-05-01 The Board of Trustees of the University of Illionis Hdac inhibitors and therapeutic methods using the same
JP6463631B2 (ja) * 2011-06-09 2019-02-06 ライゼン・ファーマシューティカルズ・エスアー Gpr−119のモジュレータとしての新規化合物
AU2016267872B2 (en) * 2015-05-22 2019-01-17 Chong Kun Dang Pharmaceutical Corp. Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
JP2022512584A (ja) 2018-10-04 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 角皮症を処置するためのegfrインヒビター

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH617318A5 (en) 1975-09-30 1980-05-30 Ciba Geigy Ag Microbicidal composition.
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
US5114937A (en) * 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
IE68045B1 (en) * 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
WO1993006127A1 (en) * 1991-09-17 1993-04-01 Warner-Lambert Company Novel amino acid prodrug renin inhibitors
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
CA2186510A1 (en) 1994-05-04 1995-11-16 Martin Zeller N-sulphonyl and n-sulphinyl amino acid amides as microbiocides
DE19507447A1 (de) 1995-03-03 1996-09-05 Vitronic Dr Ing Stein Bildvera Verfahren und Schaltung zum Erfassen und Weiterleiten von Videobilddaten in einem PC
BR9611479B1 (pt) * 1995-11-13 2009-01-13 Ácidos alfa-iminoidroxÂmicos e carboxÍlicos n-substituÍdos cÍclicos e heterocÍclicos.
ES2183905T3 (es) * 1995-12-20 2003-04-01 Hoffmann La Roche Inhibidores de metaloproteasa de matriz.
FR2748026B1 (fr) * 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
ES2136037B1 (es) 2000-11-16
NO993587L (no) 1999-09-22
AU730127B2 (en) 2001-02-22
AR011425A1 (es) 2000-08-16
ATE223909T1 (de) 2002-09-15
GB2321641B (en) 2001-04-04
KR100377696B1 (ko) 2003-03-29
ES2183331T3 (es) 2003-03-16
EP0958287A1 (en) 1999-11-24
PE57399A1 (es) 1999-06-25
KR20000070398A (ko) 2000-11-25
HUP0000941A3 (en) 2002-06-28
DK0958287T3 (da) 2003-01-20
CN1093125C (zh) 2002-10-23
TNSN98012A1 (fr) 2005-03-15
EA199900643A1 (ru) 2000-04-24
BG103586A (bg) 2000-03-31
NZ336625A (en) 2001-04-27
CN1250445A (zh) 2000-04-12
AU6614098A (en) 1998-08-18
IT1298163B1 (it) 1999-12-20
YU34599A (sh) 2002-03-18
EP0958287B2 (en) 2008-04-09
GB9801393D0 (en) 1998-03-18
FR2758559A1 (fr) 1998-07-24
IL130802A0 (en) 2001-01-28
OA11078A (en) 2003-03-17
IS5125A (is) 1999-07-22
PT958287E (pt) 2002-12-31
GB2321641A (en) 1998-08-05
DE69807845D1 (de) 2002-10-17
NO993587D0 (no) 1999-07-22
CA2278694A1 (en) 1998-07-30
DE19802350A1 (de) 1998-07-30
ID22849A (id) 1999-12-09
HRP980036A2 (en) 1998-12-31
EA002810B1 (ru) 2002-10-31
MA26467A1 (fr) 2004-12-20
EP0958287B1 (en) 2002-09-11
HUP0000941A2 (hu) 2001-04-28
JP2001523222A (ja) 2001-11-20
UY24854A1 (es) 2000-12-29
BR9807508A (pt) 2000-03-21
PA8445301A1 (es) 2001-07-31
PL334846A1 (en) 2000-03-27
ES2136037A1 (es) 1999-11-01
ITMI980091A1 (it) 1999-07-20
TR199901765T2 (xx) 1999-10-21
CA2278694C (en) 2006-09-26
WO1998032748A1 (en) 1998-07-30
JP3563411B2 (ja) 2004-09-08
DE69807845T2 (de) 2003-06-05

Similar Documents

Publication Publication Date Title
NO313635B1 (no) Sulfonamid-metalloprotease-inhibitorer, fremgangsmåter for fremstilling og anvendelse derav, og farmasöytiske preparater sominneholder dem
US6143744A (en) Sulfamide-metalloprotease inhibitors
US6376506B1 (en) Sulfamide-metalloprotease inhibitors
JP4776778B2 (ja) アリールピペラジン類および金属プロテイナーゼ阻害剤(mmp)としてのそれらの用途
AU2010326727B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP1140903B1 (en) Aromatic amides
CZ374096A3 (cs) Matricové metalloproteasové inhibitory
MX2011005925A (es) Agentes inductores de apoptosis para el tratamiento de cancer, enfermedades inmunes y autoinmunes.
TW200813073A (en) Thiazolo-pyrimidine/pyridine urea derivatives
WO2006005609A2 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
BRPI0610009A2 (pt) composto, composição farmacêutica, método para tratar um paciente que sofre de osteoporose, artrite, doença pulmonar obstrutiva crÈnica, defeitos da cartilagem, fraturas ósseas, ou leiomioma, uso de um composto tendo a fórmula (1)
US6130220A (en) Sulfamide-metalloprotease inhibitors
MXPA01007987A (es) Acido sulfamato hidroxamico inhibidor de metaloproteasa.
JP2004530691A (ja) 芳香族スルホンヒドロキサメートおよびプロテアーゼ阻害剤としてのそれらの使用
CZ255199A3 (cs) Derivát sulfamidu inhibující metaloproteázu, způsob jeho přípravy a jeho použití pro výrobu léčiv
CZ2001687A3 (cs) Arylpiperaziny a jejich použití jako činidel inhibujících metaloproteinázu (MMP)
AU2003262101A1 (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP)

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN JULY 2003